Zhejiang Huahai Pharmaceutical Co., Ltd.
600521
Rangering i aksjer
#4248
Zhejiang Huahai Pharmaceutical Co., Ltd. is a China-based pharmaceutical... Zhejiang Huahai Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise with a global presence. Its diverse portfolio encompasses treatments for central nervous system disorders, cardiovascular conditions, and viral infections, among other finished pharmaceutical products. Beyond finished drugs, the company also produces Active Pharmaceutical Ingredients (APIs) and crucial intermediates. Huahai Pharmaceutical further engages in the manufacturing of packaging components, notably high-density polyethylene (HDPE) bottles and polypropylene (PP) caps. Additionally, it offers contract manufacturing (CMO) and other specialized services, while also playing a role in import and export trade services. Established in 1989, the company maintains its headquarters in Linhai, China.
Aksjekurs
$2.49
Sist synkronisert: 2026-10-21
Markedsverdi
$3.73B
Endring (1 dag)
2.72%
Endring (1 år)
-6.10%
Land
CN
Handel Zhejiang Huahai Pharmaceutical Co., Ltd. (600521)
Kategori
Healthcare
Inntekter for Zhejiang Huahai Pharmaceutical Co., Ltd. (600521)
Inntekter i Jun 2026 TTM: $1.30B
Ifølge de nyeste økonomiske rapportene til Zhejiang Huahai Pharmaceutical Co., Ltd. er selskapets nåværende inntekter (TTM) $1.30B. I 2023 hadde selskapet inntekter på $1.17B en nedgang sammenlignet med inntektene i 2022, som var $1.20B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Zhejiang Huahai Pharmaceutical Co., Ltd. fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $1.30B | -0.47% |
| 2024 | $1.31B | 11.44% |
| 2023 | $1.17B | -2.05% |
| 2022 | $1.20B | 14.64% |
| 2021 | $1.05B | 5.29% |
| 2020 | $992.73M | 28.30% |
| 2019 | $773.78M | 4.47% |
| 2018 | $740.64M | -3.66% |
| 2017 | $768.81M | 30.42% |
| 2016 | $589.50M | 9.36% |
| 2015 | $539.03M | 29.16% |
| 2014 | $417.34M | 10.24% |
| 2013 | $378.58M | 17.20% |
| 2012 | $323.04M | 13.48% |
| 2011 | $284.66M | 83.69% |
| 2010 | $154.97M | 14.01% |
| 2009 | $135.92M | 15.73% |
| 2008 | $117.45M | 21.30% |
| 2007 | $96.82M | 34.94% |
| 2006 | $71.75M | 36.84% |
| 2005 | $52.43M | 10.94% |
| 2004 | $47.26M | 29.07% |
| 2003 | $36.62M | 61.75% |
| 2002 | $22.64M | 5.36% |
| 2001 | $21.49M | 30.66% |
| 2000 | $16.45M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 407.87% |
IN
|
